Search bioRxiv⌕ Search

Biology subjects

Atanda, H. C.

Publications and source records attributed to Atanda, H. C..

2 recordsLinked to original sources

Substantial genomic and methylation variability between MCF-7 sublines

Cancer cell lines have long been used as in vitro models for molecular assays in diagnostic and therapeutic development due to their accessibility as a well-controlled system. MCF-7 cell lines are the most widely studied cell lines in human breast cancer research, and its sublines have been reported to exhibit clonal, cytogenetic, and transcriptomic variability. However, allele-specific methylation alterations in cancer genomes remain inadequately explored, largely due to limitations in sequencing methods. Here, we applied nanopore sequencing technology to characterise the genomic and epigenomic landscapes of two MCF-7 sublines. We identified global and local DNA methylation differences as well as structural variants (SVs), and single-nucleotide variants (SNVs) between and within the sublines. Our analysis revealed substantial divergence in methylation patterns between the sublines, with [~]3% of the differentially methylated regions (DMRs) overlapping with known cancer driver genes. These DMRs overlap breast cancer-associated genes, including ERBB2, CDH1, SALL4, GATA2, GATA3, HMGA2, and FBLN2. We find that the majority of differentially methylated sites are explained by differential allelic methylation, and that allele-specific DMRs often overlap points where antisense non-coding RNAs overlap protein-coding genes. Transposable elements in both sublines also showed distinct methylation profiles, with one subline having hypomethylated L1 elements compared to the other, which correlated with the amount of apparent insertional mutagenesis attributable to L1 between the sublines. Our study demonstrates the utility of nanopore sequencing in providing novel insights into genomic and methylomic differences within cell lines, in addition to insight into the nature of differential allelic methylation.

genomics↗

Computational Identification of Potential Inhibitors Targeting cdk1 in Colorectal Cancer

Despite improved treatment options, colorectal cancer (CRC) remains a huge public health concern with a significant impact on affected individuals. Cell cycle dysregulation and overexpression of certain regulators and checkpoint activators are important recurring events in the progression of cancer. Cyclin-dependent kinase 1 (CDK1), a key regulator of the cell cycle component central to the uncontrolled proliferation of malignant cells, has been reportedly implicated in CRC. This study aimed to identify CDK1 inhibitors with potential for clinical drug research in CRC. Ten thousand (10,000) naturally occurring compounds were evaluated for their inhibitory efficacies against CDK1 through molecular docking studies. The stability of the lead compounds in complex with CDK1 was evaluated using molecular dynamics simulation for one thousand (1,000) nanoseconds. The top-scoring candidates ADME characteristics and drug-likeness were profiled using SwissADME. Four hit compounds namely spiraeoside, robinetin, 6-hydroxyluteolin, and quercetagetin were identified from molecular docking analysis to possess the least binding scores. Molecular dynamics simulation revealed that robinetin and 6-hydroxyluteolin complexes were stable within the binding pocket of the CDK1 protein. The findings from this study provide insight into novel candidates with specific inhibitory CDK1 activities that can be further investigated through animal testing, clinical trials, and drug development research for CRC treatment.

bioinformatics↗